0001127602-20-016619.txt : 20200514 0001127602-20-016619.hdr.sgml : 20200514 20200514170007 ACCESSION NUMBER: 0001127602-20-016619 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200512 FILED AS OF DATE: 20200514 DATE AS OF CHANGE: 20200514 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kim Lorence H. CENTRAL INDEX KEY: 0001643746 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38753 FILM NUMBER: 20878685 MAIL ADDRESS: STREET 1: C/O SERES HEALTH, INC. STREET 2: 161 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02472 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Moderna, Inc. CENTRAL INDEX KEY: 0001682852 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813467528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6177146500 MAIL ADDRESS: STREET 1: 200 TECHNOLOGY SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Moderna Therapeutics, Inc. DATE OF NAME CHANGE: 20160822 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2020-05-12 0001682852 Moderna, Inc. MRNA 0001643746 Kim Lorence H. C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 1 Chief Financial Officer Common Stock 2020-05-12 4 M 0 11643 12.21 A 1234153 D Common Stock 2020-05-12 4 M 0 229357 10.90 A 1463510 D Common Stock 2020-05-12 4 S 0 35182 62.56 D 1428328 D Common Stock 2020-05-12 4 S 0 31948 63.57 D 1396380 D Common Stock 2020-05-12 4 S 0 104544 64.67 D 1291836 D Common Stock 2020-05-12 4 S 0 61412 65.47 D 1230424 D Common Stock 2020-05-12 4 S 0 5677 66.43 D 1224747 D Common Stock 2020-05-12 4 S 0 2237 67.32 D 1222510 D Stock Option (Right to Buy) 10.90 2020-05-12 4 M 0 229357 0 D 2026-02-23 Common Stock 229357 0 D Stock Option (Right to Buy) 12.21 2020-05-12 4 M 0 11643 0 D 2027-02-23 Common Stock 11643 286522 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.04 to $63.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.07 to $64.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.09 to $65.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.10 to $66.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.12 to $66.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.16 to $67.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. This option is fully vested and exercisable. 25% of this option vested and became exercisable on February 22, 2018, with the remainder vesting in 12 equal quarterly installments thereafter. /s/ Lori Henderson, as Attorney-in-Fact 2020-05-14